Catabasis Pharmaceuticals Inc News Releases http://ir.catabasis.com/ Catabasis Pharmaceuticals Inc News Releases en Catabasis Pharmaceuticals Reports First Quarter 2019 Financial Results and Reviews Business Progress http://ir.catabasis.com/news-releases/news-release-details/catabasis-pharmaceuticals-reports-first-quarter-2019-financial -- Edasalonexent Phase 3 PolarisDMD Trial in Duchenne Muscular Dystrophy Enrolling Boys Globally -- -- Sustained Slowing of DMD Disease Progression with Edasalonexent Reinforced by Long Term MoveDMD MRI Data -- CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 14, 2019-- Catabasis Pharmaceuticals, Inc. Tue, 14 May 2019 08:05:00 -0400 Catabasis Pharmaceuticals Inc News Releases 8616 Catabasis Pharmaceuticals to Present Data from the MoveDMD® trial of Edasalonexent in Duchenne Muscular Dystrophy at the American Academy of Neurology 71st Annual Meeting http://ir.catabasis.com/news-releases/news-release-details/catabasis-pharmaceuticals-present-data-movedmdr-trial CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 2, 2019-- Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that it will present data on edasalonexent treatment in boys affected by Duchenne muscular dystrophy (DMD) from the MoveDMD trial open-label Thu, 02 May 2019 08:00:00 -0400 Catabasis Pharmaceuticals Inc News Releases 8596 Catabasis Pharmaceuticals to Report First Quarter 2019 Financial Results and Recent Corporate Developments on Tuesday, May 14th http://ir.catabasis.com/news-releases/news-release-details/catabasis-pharmaceuticals-report-first-quarter-2019-financial The company will host a conference call at 8:30am ET CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 30, 2019-- Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, will report first quarter 2019 financial results before the Nasdaq Global Market open on Tuesday, May Tue, 30 Apr 2019 08:00:00 -0400 Catabasis Pharmaceuticals Inc News Releases 8591 Catabasis Pharmaceuticals to Present at Upcoming Neuromuscular Translational Research Conference and MDA Clinical and Scientific Conference http://ir.catabasis.com/news-releases/news-release-details/catabasis-pharmaceuticals-present-upcoming-neuromuscular CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 1, 2019-- Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that it will present edasalonexent program data, including from the Phase 2 MoveDMD trial and open-label extension, and the design of the Mon, 01 Apr 2019 08:00:00 -0400 Catabasis Pharmaceuticals Inc News Releases 8566 Catabasis Pharmaceuticals and CureDuchenne to Host Webinar on Edasalonexent in Development for the Treatment of Duchenne http://ir.catabasis.com/news-releases/news-release-details/catabasis-pharmaceuticals-and-cureduchenne-host-webinar Thu, 14 Mar 2019 15:00:00 -0400 Catabasis Pharmaceuticals Inc News Releases 8561 Catabasis Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Reviews Business Progress http://ir.catabasis.com/news-releases/news-release-details/catabasis-pharmaceuticals-reports-fourth-quarter-and-full-year-2 -- Edasalonexent Phase 3 PolarisDMD Trial Globally Enrolling Boys with Duchenne Muscular Dystrophy -- CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 14, 2019-- Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today reported financial results for the fourth Thu, 14 Mar 2019 08:05:00 -0400 Catabasis Pharmaceuticals Inc News Releases 8551 Catabasis Pharmaceuticals to Present at Oppenheimer’s 29th Annual Healthcare Conference http://ir.catabasis.com/news-releases/news-release-details/catabasis-pharmaceuticals-present-oppenheimers-29th-annual CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 13, 2019-- Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that Jill C. Milne , Ph.D., Chief Executive Officer, will present a corporate overview at Oppenheimer’s 29 th Annual Healthcare Conference Wed, 13 Mar 2019 08:00:00 -0400 Catabasis Pharmaceuticals Inc News Releases 8536 Catabasis Pharmaceuticals to Report Fourth Quarter and Full Year 2018 Financial Results and Recent Corporate Developments on Thursday, March 14 http://ir.catabasis.com/news-releases/news-release-details/catabasis-pharmaceuticals-report-fourth-quarter-and-full-year-2 The Company Will Host a Conference Call at 8:30am ET CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 28, 2019-- Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, will report fourth quarter and full year 2018 financial results before the Nasdaq Global Market open on Thu, 28 Feb 2019 08:00:00 -0500 Catabasis Pharmaceuticals Inc News Releases 8531 Catabasis Pharmaceuticals Presents Data Supporting Edasalonexent as a Potential Foundational Treatment for Duchenne Muscular Dystrophy http://ir.catabasis.com/news-releases/news-release-details/catabasis-pharmaceuticals-presents-data-supporting-edasalonexent -- Boys on Edasalonexent Grew More than Two Inches Taller per Year on Average -- CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 19, 2019-- Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today shared additional clinical results from the MoveDMD trial of Tue, 19 Feb 2019 08:00:00 -0500 Catabasis Pharmaceuticals Inc News Releases 8521 Catabasis Pharmaceuticals Appoints Joanne T. Beck to its Board of Directors http://ir.catabasis.com/news-releases/news-release-details/catabasis-pharmaceuticals-appoints-joanne-t-beck-its-board CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 14, 2019-- Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced the appointment of Joanne T. Beck, Ph.D., to its Board of Directors. Dr. Beck has more than 25 years of pharmaceutical development and Thu, 14 Feb 2019 08:00:00 -0500 Catabasis Pharmaceuticals Inc News Releases 8471